IP Library Granted Patent US 7,136,699
Granted Patent B2
US 7,136,699 · App. 10/263,329 · Granted Nov 14, 2006

Apparatus for destroying dividing cells

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,136,699
App. No.
10/263,329
Granted
Nov 14, 2006
Kind
B2
Abstract

An apparatus is provided for selectively destroying dividing cells in living tissue formed of dividing cells and non-dividing cells. The dividing cells contain polarizable intracellular members and during late anaphase or telophase, the dividing cells are connected to one another by a cleavage furrow. The apparatus includes a generator and insulated electrodes for subjecting the living tissue to electric field conditions sufficient to cause movement of the polarizable intracellular members toward the cleavage furrow in response to a non-homogeneous electric field being induced in the dividing cells. The non-homogeneous electric field produces an increased density electric field in the region of the cleavage furrow. The movement of the polarizable intracellular intracellular members towards the cleavage furrow causes the breakdown thereof which results in the destruction of the dividing cells, while the non-dividing cells of the living tissue remain intact.

Claims (57)

1. An apparatus for selectively destroying dividing cells in living tissue, the dividing cells having polarizable or polar intracellular members, the apparatus comprising:

a first insulated electrode having a first conductor and a first insulating layer, wherein the first insulated electrode is configured for placement against the living tissue with the first insulating layer disposed between the first conductor and the living tissue so as to insulate the first conductor from the living tissue;

a second insulated electrode having a second conductor and a second insulating layer, wherein the second insulated electrode is configured for placement against the living tissue with the second insulating layer disposed between the second conductor and the living tissue so as to insulate the second conductor from the living tissue; and

an electric field source for applying an alternating electric potential across the first and second conductors,

wherein the amplitude and frequency of the electric field source and the capacitance of the insulating layers are such that, when the electrodes are placed against the living tissue and the alternating electric potential is applied across the first and second conductors, an electric field is induced in the living tissue, the induced electric field having characteristics such that passage of the electric field through the dividing cells in late anaphase or telophase transforms the electric field into & non-homogenous electric field that produces an increased density electric field in a region of a cleavage furrow of the dividing cells, the non-homogeneous electric field produced within the dividing cells being of sufficient intensity to move the polarizable intracellular members toward the cleavage.

2. The apparatus of claim 1 , wherein the electric field is of sufficient frequency so that the non-homogeneous electric field produced in the dividing cells defines electric field lines which generally converge at a region of the cleavage furrow, thereby defining the increased density electric field, resulting in destruction of the dividing cells as a result of the polarizable intracellular members movement toward the furrow.

3. The apparatus of claim 1 , further including:

a first conductive lead operatively connecting the first electrode to the electric field source; and

a second conductive lead operatively connecting the second electrode to the electric field source.

4. The apparatus of claim 1 , wherein the first electrode includes a first dielectric member that is in contact with the first conductor, the first dielectric member for placement against the living tissue to form a capacitor.

5. The apparatus of claim 4 , wherein the second electrode includes a second dielectric member that is in contact with the second conductor, the second dielectric member for placement against the living tissue to form a capacitor.

6. The apparatus of claim 5 , wherein each of the first and second dielectric members is formed of a layer of titanium dioxide.

7. The apparatus of claim 5 , wherein each of the first and second dielectric members comprises a dielectric coating having a thickness between about 5 microns to about 50 microns.

8. The apparatus of claim 7 , further including: a loose net disposed around the dielectric coating for restricting access to a surface of the dielectric coating while only having a minimal effect on a surface area of the dielectric coating.

9. The apparatus of claim 7 , further including: a thin conducting coating disposed on the dielectric coating for contacting the tissue.

10. The apparatus of claim 9 , wherein the conducting coating is formed of gold.

11. The apparatus of claim 5 , wherein at least one of the first and second electrodes includes an intervening filler disposed on the respective dielectric member thereof, the intervening filler being formed of a material that has high conductance and a high dielectric constant.

12. The apparatus of claim 11 , wherein the intervening filler comprises a gel formed of at least one material selected from the group consisting of gelatins and agar.

13. The apparatus of claim 12 , wherein the gel includes salt dissolved therein to increase the conductivity of the gel.

14. The apparatus of claim 11 , wherein the intervening filler is contained within the dielectric member by a rim formed as part of the dielectric member.

15. The apparatus of claim 1 , wherein the alternating electric potential has a frequency of between about 50 KHz to about 500 KHz.

16. The apparatus of claim 1 , wherein the alternating electric potential has a frequency of between about 100 KHz to about 300 KHz.

17. The apparatus of claim 1 , wherein the electric field is a substantially uniform electric field prior to passing through the dividing cells.

18. The apparatus of claim 1 , wherein the electric field source comprises a generator that generates an alternating voltage waveform at frequencies between about 50 KHz to about 500 KHz.

19. The apparatus of claim 18 , wherein each of the first and second electrodes are activated by the alternating voltage waveform.

20. The apparatus of claim 18 , wherein the voltage waveform is selected so that an electric field intensity in tissue to be treated is between about 0.1 V/cm to about 10.0 V/cm.

21. The apparatus of claim 1 , further including:

a control box operatively connected to the electric field source; and

a temperature sensor coupled to the control box, wherein the control box and the temperature sensor control the amplitude of the electric field generated so that excessive heating in a treated area is prevented.

22. The apparatus of claim 1 , wherein the first and second electrodes are adapted to be inserted within a body.

23. The apparatus of claim 22 , wherein the first and second electrodes are incorporated into a structure that is adapted to be inserted subcutaneously within the body.

24. The apparatus of claim 1 , wherein the first and second electrodes are configured for placement on opposite sides of a torso with the dividing cells being associated with a tumor that is formed within the body at a location between the first and second electrodes.

25. A skin patch for selectively destroying dividing cells that are in a localized area of living tissue, the dividing cells having polarizable or polar intracellular members, the skin patch including:

a skin patch body for placement on the living tissue over the localized area of dividing cells, the skin patch body comprising: a first insulated electrode having a first conductor and a first insulating layer disposed between the first conductor and the living tissue so as to insulate the first conductor from the living tissue; and a second insulated electrode having a second conductor and a second insulating layer disposed between the second conductor and the living tissue so as to insulate the second conductor from the living tissue; and

an electric field source for applying an alternating electric potential across the first and second conductors,

wherein the amplitude and frequency of the electric field source and the capacitance of the insulating layers are such that, when the skin patch body is placed against the living tissue and the alternating electric potential is applied across the first and second conductors, an electric field is induced in the living tissue, the induced electric field having characteristics such that passage of the electric field through the dividing cells in late anaphase or telophase transforms the electric field into a nonhomogenous electric field that produces an increased density electric field in a region of a cleavage furrow of the dividing cells, the non-homogeneous electric field produced within the dividing cells being of sufficient intensity to move the polarizable intracellular members toward the cleavage furrow.

26. The skin patch of claim 25 , wherein the electric field is of sufficient frequency so that the non-homogeneous electric field produced in the dividing cells defines electric field lines which generally converge at a region of the cleavage furrow, thereby defining the increased density electric field, resulting in destruction of the dividing cells as a result of the polarizable intracellular members movement toward the furrow.

27. The skin patch of claim 25 , wherein the alternating electric potential has a frequency of between about 50 KHz to about 500 KHz.

28. The skin patch of claim 25 , wherein the alternating electric potential has a frequency of between about 100 KHz to about 300 KHz.

29. The skin patch of claim 25 , wherein the electric field is a substantially uniform electric field prior to passing through the dividing cells.

30. The skin patch of claim 29 , wherein each of the first and second electrodes are activated by the alternating voltage waveform.

31. The skin patch of claim 29 , wherein the voltage waveform is selected so that an electric field intensity in tissue to be treated is between about 0.1 V/cm to about 10.0 V/cm.

32. The skin patch of claim 25 , wherein the electric field source comprises a generator that generates an alternating voltage waveform at frequencies between about 50 KHz to about 500 KHz.

33. The skin patch of claim 25 , further including:

a control box operatively connected to the electric field source;

and a temperature sensor coupled to the control box, wherein the control box and the temperature sensor control the amplitude of the electric field generated so that excessive heating in a treated area is prevented.

34. The skin patch of claim 25 , further comprising: at least one additional insulated electrode having a corresponding conductor that is coupled to the electric field source.

35. The skin patch of claim 34 , wherein all of the insulated electrodes are arranged to focus the electric field at a target within the localized area of the living tissue while also forming a protected area which has a low electric field density.

36. An apparatus for selectively destroying dividing cells in living tissue, the dividing cells having polarizable or polar intracellular members, the apparatus comprising:

a first insulated electrode having a first conductor and a first insulating layer, wherein the first insulated electrode is configured for placement against the living tissue with the first insulating layer disposed between the first conductor and the living tissue so as to insulate the first conductor from the living tissue;

a second insulated electrode having a second conductor and a second insulating layer, wherein the second insulated electrode is configured for placement against the living tissue with the second insulating layer disposed between the second conductor and the living tissue so as to insulate the second conductor from the living tissue; and

an electric field source for applying an alternating electric potential across the first and second conductors,

wherein the amplitude an& frequency of the electric field source and the capacitance of the insulating layers are such that, when the electrodes arc placed against the living tissue and the alternating electric potential is applied across the first and second conductors, an electric field is induced in the living tissue, the induced electric field having characteristics such that (a) passage of the electric field through the dividing cells in late anaphase or telophase kills a significant portion of the dividing cells, and (b) passage of the electric field through non-dividing cells leaves the non-dividing cells substantially unharmed.

37. A skin patch far selectively destroying dividing cells that are in a localized area of living tissue, the dividing cells having polarizable or polar intracellular members, the skin patch including:

a skin patch body for placement on the living tissue over the localized area of dividing cells, the skin patch body comprising: a first insulated electrode having a first conductor and a first insulating layer disposed between the first conductor and the living tissue so as to insulate the first conductor from the living tissue; and a second insulated electrode having a second conductor and a second insulating layer disposed between the second conductor and the living tissue so as to insulate the second conductor from the living tissue; and

an electric field source for applying an alternating electric potential across the first and second conductors,

wherein the amplitude and frequency of the electric field source and the capacitance of the insulating layers are such that, when the skin patch body is placed against the living tissue and the alternating electric potential is applied across the first and second conductors, an electric field is induced in the living tissue, the induced electric field having characteristics such that (a) passage of the electric field through the dividing cells in late anaphase or telophase kills a significant portion of the dividing cells, and (b) passage of the electric field through non-dividing cells leaves the non-dividing cells substantially unharmed.

Assignments (17)
PATENT SECURITY AGREEMENT Recorded May 4, 2024
From: NOVOCURE GMBH (SWITZERLAND)
To: BIOPHARMA CREDIT PLC
Reel/Frame 067315/0399 →
RELEASE OF SECURITY INTEREST Recorded Apr 24, 2024
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: NOVOCURE GMBH
Reel/Frame 067211/0839 →
SECURITY INTEREST Recorded Nov 6, 2020
From: NOVOCURE GMBH
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 054344/0510 →
RELEASE OF SECURITY INTEREST FOR PATENT SECURITY AGREEMENT FILED AT REEL/FRAME 45278 0825 Recorded Aug 25, 2020
From: BIOPHARMA CREDIT PLC
To: NOVOCURE LIMITED
Reel/Frame 053597/0335 →
RELEASE OF SECURITY INTEREST FOR PATENT SECURITY AGREEMENT FILED AT REEL/FRAME 50395/0398 Recorded Aug 19, 2020
From: BPCR LIMITED PARTNERSHIP
To: NOVOCURE GMBH
Reel/Frame 053538/0623 →
OMNIBUS CONFIRMATION OF ASSIGNMENT AGREEMENT Recorded May 21, 2020
From: BIOPHARMA CREDIT PLC
To: BPCR LIMITED PARTNERSHIP
Reel/Frame 052741/0173 →
RELEASE OF SECURITY INTEREST FOR PATENT SECURITY AGREEMENT FILED AT REEL/FRAME 045278/0825 Recorded Apr 14, 2020
From: BIOPHARMA CREDIT PLC
To: NOVOCURE LIMITED
Reel/Frame 052391/0549 →
RELEASE OF SECURITY INTEREST Recorded Apr 13, 2020
From: BIOPHARMA CREDIT PLC
To: NOVOCURE LIMITED
Reel/Frame 052383/0705 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2019
From: NOVOCURE LIMITED
To: NOVOCURE GMBH
Reel/Frame 050110/0098 →
SECURITY INTEREST Recorded May 6, 2019
From: NOVOCURE GMBH
To: BIOPHARMA CREDIT PLC
Reel/Frame 050395/0398 →
SECURITY INTEREST Recorded Feb 7, 2018
From: NOVOCURE LIMITED
To: BIOPHARMA CREDIT PLC
Reel/Frame 045278/0825 →
RELEASE OF SECURITY INTEREST Recorded Feb 7, 2018
From: BIOPHARMA SECURED INVESTMENTS III HOLDINGS CAYMAN LP
To: NOVOCURE LIMITED
Reel/Frame 044858/0416 →
SECURITY INTEREST Recorded Feb 7, 2018
From: NOVOCURE LIMITED
To: BIOPHARMA CREDIT PLC
Reel/Frame 045284/0851 →
SECURITY INTEREST Recorded Feb 2, 2015
From: NOVOCURE LIMITED
To: BIOPHARMA SECURED INVESTMENTS III HOLDINGS CAYMAN LP
Reel/Frame 034866/0402 →
RELEASE OF SECURITY INTEREST Recorded Dec 20, 2013
From: DEUTSCHE BANK TRUST COMPANY AMERICAS
To: NOVOCURE LIMITED
Reel/Frame 031866/0567 →
SECURITY AGREEMENT Recorded Feb 20, 2013
From: NOVOCURE LIMITED
To: DEUTSCHE BANK TRUST COMPANY AMERICAS
Reel/Frame 029845/0135 →
CHANGE OF NAME Recorded May 19, 2011
From: STANDEN LIMITED
To: NOVOCURE LIMITED
Reel/Frame 026311/0210 →